👋 Meet our Genitourinary Section Editor: Georgios Agrotis, MD, PhD
Check out our editorial board: https://t.co/6giDEpyXsq
🙏 Thank you for your dedication and for being a valued member of the EJR editorial team.
We’re delighted to announce #ICIS2026!
📍 Belfast, Northern Ireland
🏨 The Europa Hotel
📅 23–25 September
Welcome to our incoming President, Prof Anju Sahdev, of St Bart’s, London, who's forming her Scientific Committee. Stay tuned for programme highlights and speaker details!
Magnetic Resonance Imaging–based Biopsy Strategies in Prostate Cancer Screening: A Systematic Review
https://t.co/nqcih8eYdU
Systematic review evaluated the benefit–harm balance of incorporating magnetic resonance imaging (MRI) into #ProstateCancer (PCa) screening as either a first-line test or a second-stage test after PSA >3 ng/ml. Across five first-line and four second-stage studies, MRI strategies were compared for cancer detection, biopsy avoidance, and histological outcomes. First-line MRI identified roughly twice as many clinically significant (GG ≥2) cancers as second-stage MRI but left a higher proportion of men MRI-negative, while second-stage MRI markedly reduced biopsy rates and increased the detection ratio of GG ≥2 versus GG 1 cancers with both targeted and systematic biopsies.
Both approaches achieved positive benefit-to-harm ratios (>1), indicating net clinical benefit, though first-line MRI needs further feasibility evaluation and standardisation of MRI interpretation and biopsy protocols is essential for consistent screening quality.
@IvoSchootsNL@LondonProstate1@albers_pa@AsbachP@roodvdb@TobiasNordstrom@ShonitP@ProfPadhani@OncoAlert 🚨
@Silke_Gillessen@AOmlin@nataliagandur@bavilima
Prof. Jens Vogel-Claussen übernimmt die Professur für #Radiologie & leitet die gleichnamige Klinik der #CharitéBerlin. Fokus: Früherkennung, schonende Bildgebung & interdisziplinäre Zusammenarbeit für Patient:innen. Unterstützt durch @stiftungcharite. 🫰 https://t.co/9AQrizbkju
Join us for this new ICISi Masterclass in Rectal Cancer MRI which will explore staging, restaging, rad-path, image quality and watch & wait.
Register now, this ONLINE course will be delivered over 2 half days: 16th - 17th October 2025, from 8:00am.
🔗 https://t.co/jOfrtx39an
Less than 2 months till #ICIS2025!
With the theme 'Precision Diagnostics: Advancing Oncological Imaging Breakthroughs' this event will cover the latest in molecular imaging, radiomics, AI & next-generation techniques & much more
📍 The Hague
📅 24-26 Sep
🔗https://t.co/PltOwZfqlc
Join us for this brand new ICISi Masterclass in Rectal Cancer MRI which will explore staging, restaging, rad-path, image quality and watch & wait.
This course takes place over 2 half days, starting at 8am on Thursday 16th and Friday 17th October 2025.
https://t.co/jOfrtx2BkP
🚨Free webinar🚨
Prof Anwar Padhani and Prof Hashim Ahmed will explore the urological and radiological challenges when imaging prostate cancer.
Wednesday 23 April, 12:30 (British Summer Time)
🔗 Sign up for this one-hour session here: https://t.co/z7PtqmRttT
Read about our 2025 teaching courses, free webinars, and much more in the International Cancer Imaging Society December eNewsletter 🎄
https://t.co/XT3xVXKWLx
Most viewed in the last 7 days from @JAMAOnc:
Men with negative multiparametric MRI results avoiding biopsy were not at elevated risk of clinically significant prostate cancer.
https://t.co/i5Zs3uor8O
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected #ProstateCancer
https://t.co/oIuyMVjh7u
This cohort study assessed the safety of omitting prostate biopsy (PB) in men with suspected prostate cancer who had negative multiparametric MRI (mpMRI) results. Among 593 men studied, 48% had negative MRI results, and 86% of these men avoided biopsy over a 3-year period with ongoing clinical monitoring. After 3 years, only 4% of men with negative MRI results were diagnosed with clinically significant prostate cancer (csPCa).
The findings suggest that prebiopsy MRI has a high negative predictive value, allowing men with negative MRI results to safely avoid PB when they are closely monitored. This approach supports the use of MRI to reduce unnecessary biopsies without compromising cancer detection.
@Charlie_Charite@AsbachP@IvoSc@CashHannes
📅 Save the date for ICIS 2025!
ICIS President, Prof. Thierry Huisman, warmly invites you to attend his meeting. Our 24th annual teaching course will take place in The Hague Conference Centre, from Wednesday 24 to Friday 26 September.
"The lack of evidence about the utilization and timing of mpMRI in active surveillance (AS) can potentially lead to over or underutilization of this relatively scarce resource. Defining the optimal imaging interval for mpMRI could improve cost-effectiveness by eliminating unnecessarily frequent mpMRIs for men on AS." - Rebecca A. Campbell et al.
#EuropeanRadiology
🔗 https://t.co/fG7V8re8LB